In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

How to understand personalized antithrombotic therapy in cardio-oncology

In this video, Doctor Anna Falanga (Department of Transfusion Medicine and Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy) joins Associate Professor Sebastian Szmit (The Medical Centre of Postgraduate Education, Warsaw, Poland) to discuss how to understand personalized antithrombotic therapy in cardio-oncology.

References

1. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
HemaSphere 6(8):p e750, August 2022. | DOI: 10.1097/HS9.0000000000000750